Piper Jaffray analyst Matt O’Brien kept his Neutral rating and $10 price target on Endologix after its in-line Q1 results. The analyst says investors should monitor signs of “stabilization” in the company’s U.S. business amid continued operational risks this year along with its cash burn, adding that the tone of Endologix earnings call was “brighter” but also conservative.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.